Compare Boston Scientific Corporation (BSX) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Infosys Limited — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Infosys Limited trades at $11.05 (market cap $46.90B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Infosys Limited pays a 4.74% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | INFY | |
|---|---|---|
Market Cap | $66.37B | $46.90B |
Sector | Health | Technology |
52-Week High | $108.14 | $20.22 |
52-Week Low | $42.63 | $10.49 |
Enterprise Value | $75.94B | $44.12B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
INFY trades at $11.50, up 5.12% today, with a bullish technical signal and strong profitability metrics including a 16.44% net income margin and 31.57% ROE. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company is actively expanding AI collaborations in healthcare and financial services, as reported by PRNewsWire on June 24, 2026.
The stock offers a moderate valuation with a P/E of 13.81 and consensus price target of $12.14, suggesting modest upside. Risks include competitive pressures from AI automation and volatile IT spending, but institutional sentiment is mixed with 37.5% buy ratings. The dividend yield adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
